A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer

BACKGROUND: The treatment of extensive stage small‐cell lung cancer (ES‐SCLC) has only made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, approved for the treatment of SCLC by January 2022. However, currently, there is limited real‐wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Guihuan, Wang, Fei, Xie, Xiaohong, Liu, Ting, Zeng, Chen, Chen, Ziyao, Zhou, Maolin, Deng, Haiyi, Yang, Yilin, Lin, Xinqing, Xie, Zhanhong, Sun, Gengyun, Zhou, Chengzhi, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417203/
https://www.ncbi.nlm.nih.gov/pubmed/37462138
http://dx.doi.org/10.1002/cam4.5843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417203/
https://www.ncbi.nlm.nih.gov/pubmed/37462138
http://dx.doi.org/10.1002/cam4.5843

Ejemplares similares